Sugi Predict

Sugi Predict / Compounds / Vonafexor

Vonafexor

Vonafexor

SCHEMBL1893285

O=C(O)c1cc2c(Cl)c(N3CCN(S(=O)(=O)c4c(Cl)cccc4Cl)CC3)ccc2o1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 1/20 0.81
▸ POLB P06746 2/20 0.44
▸ CNR1 P21554 1/20 0.43
▸ HPGD P15428 2/20 0.41
▸ ATM Q13315 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ GLA P06280 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PIM1 P11309 2/20 0.38
▸ CSNK2A1 P68400 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890319 0.96 NR1H4 (0.75) NR1H4POLBCNR1HPGDATM
SCHEMBL1892800 0.91 NR1H4 (0.80) NR1H4POLBCNR1HPGDATM
SCHEMBL29881035 0.90 NR1H4 (0.66) NR1H4HPGDKMT2AGLAALDH1A1
SCHEMBL1894860 0.90 NR1H4 (0.66) NR1H4HPGDKMT2AGLAALDH1A1
SCHEMBL29881011 0.90 NR1H4 (1.00) NR1H4POLBCNR1HPGDKMT2A
SCHEMBL1888135 0.90 NR1H4 (1.00) NR1H4POLBCNR1HPGDKMT2A
SCHEMBL29174572 0.89 NR1H4 (0.77) NR1H4POLBCNR1HPGDATM
SCHEMBL30725404 0.89 NR1H4 (0.77) NR1H4POLBCNR1HPGDATM
SCHEMBL1890553 0.88 NR1H4 (0.64) NR1H4HPGDKMT2AGLAALDH1A1
SCHEMBL29881015 0.88 NR1H4 (0.64) NR1H4HPGDKMT2AGLAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743451-A1 TROMETHAMINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF ENYO Pharma (FR) 2026-05-20 — — EP claimed
EP-4743450-A1 L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF ENYO Pharma (FR) 2026-05-20 — — EP claimed
EP-4743449-A1 L-ARGININE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF ENYO Pharma (FR) 2026-05-20 — — EP claimed
US-20260076956-A1 METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF US GOV VETERANS AFFAIRS (US) 2026-03-19 — — US claimed
US-12551480-B2 Treatment using EYP001 ENYO PHARMA (FR) 2026-02-17 — — US claimed
EP-4676518-A1 SYNERGISTIC EFFECT OF AN FXR AGONIST AND IFN FOR THE TREATMENT OF CHRONIC HDV INFECTION ENYO Pharma (FR) 2026-01-14 — — EP claimed
EP-3999100-B1 IMPROVED TREATMENT USING EYP001 ENYO PHARMA (FR) 2025-08-20 — — EP claimed
WO-2025131019-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) 2025-06-26 — — WO claimed
US-20250188473-A1 Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors REGENERON PHARMACEUTICALS, INC. 2025-06-12 — — US claimed
EP-4090327-B1 USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS INST NAT SANTE RECH MED (FR) 2025-03-05 — — EP claimed
WO-2022083853-A1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR GBIOTECH S.À.R.L. (CH) 2022-04-28 — — WO claimed
CN-114173784-A Method for reducing side effects of interferon 埃尼奥制药公司 2022-03-11 — — CN claimed
CN-114051411-A Synergistic effect of EYP001 and IFN for treating HBV infection 埃尼奥制药公司 2022-02-15 — — CN claimed
CN-114025760-A Improved treatment with EYP001 埃尼奥制药公司 2022-02-08 — — CN claimed
EP-2262785-B1 BENZOFURANE DERIVATIVES AS FXR MODULATORS MERCK PATENT GMBH (DE) 2015-01-14 — — EP claimed
US-8575161-B2 Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators MERCK PATENT GMBH (DE) 2013-11-05 — — US claimed
US-20110105475-A1 BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS MERXCK PATENT GESELLSCHAFT (DE) 2011-05-05 — — US claimed
EP-2262785-A1 BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS Merck Patent GmbH (DE) 2010-12-22 — — EP claimed
WO-2009127321-A1 BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS MERCK PATENT GMBH, (DE) 2009-10-22 — — WO claimed
EP-2110374-A1 Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators Merck Sante (FR) 2009-10-21 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076956-A1 METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF COL1A1, COL2A1, FN1 NR1H4 250/4885POLB 3091/4885CNR1 171/4885
US-20110105475-A1 BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS FXR1, FXR2, NR1H4 NR1H4 3/4885POLB 3866/4885CNR1 752/4885
US-12551480-B2 Treatment using EYP001 SLC10A1, APOB, NR1H4 NR1H4 3/4885POLB 895/4885CNR1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.